Raised hands appear from the bottom of the image with the text "HELP US STOP-T1D". The background of the image is pale green and contains Y-shaped autoantibodies arranged into the shape of a stop sign.
Research Spotlight
Read more
New prevention study now open for enrollment – Help us find out if a low dose immunotherapy can STOP-T1D
TrialNet researchers are testing low-dose anti-thymocyte globulin (ATG), an immunotherapy, to find out if it can delay or prevent type 1 diabetes (T1D) in people at high risk of clinical diagnosis (Stage 3) within two years.
DECA Executive Director Terry posing for a photo with family members on a dock: wife, daughter, son-in-law, grandchild, and dog
Media Release
Read more
Diabetes camps provide summer fun and independence
DECA Executive Director Terry Ackley, and his wife, Carol, volunteered at Camp Seale Harris for several years before he was hired as the Camp’s executive director in 1995. He served in that role until joining DECA in 2012. Pictured here: Terry and Carol (right) with daughter, Emily (left), son-in-law, Patrick, and granddaughter, Vivienne.
Screenshot of Diabetes Care showing the title of the findings from TrialNet's Abatacept Prevention Study
Study Findings
Read more
Study findings shed new light on abatacept’s impact on type 1 diabetes progression, suggest direction for additional research
Findings from the TrialNet Abatacept Prevention Study, published online in Diabetes Care, provide important new information about how abatacept impacts type 1 diabetes (T1D) progression and suggest direction for additional research.
